Search

Your search keyword '"Valadier J"' showing total 6 results
Start Over Author "Valadier J" Language english
6 results on '"Valadier J"'

2. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

Author

Henri Panjo, Guillemette Unal, François Simon, Jean-Christophe Plantier, Elodie Alessandri-Gradt, Diane Descamps, Charlotte Charpentier, Juliette Pavie, Marie Leoz, Francis Barin, Laurence Meyer, Clément Lefèvre, Orivao Study, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Faculté de Médecine [Université Paris Diderot - Paris 7], Université Paris Diderot - Paris 7 (UPD7), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), ORIVAO Study : Chennebault J, Fialaire P, Le Guillou-Guillemette H, Rehaiem S, Chanzy B, Clavere G, Gaillat J, Courdavault L, Genet P, Gerbe J, Benoit C, Honore Bouakline S, Waldner A, Bettinger D, Chirouze C, Bernard N, Reigadas S, Dupont X, Gaillard JL, Gault E, Reimann E, Otterbein G, Thomas L, Vaghefi P, Benoit M, Buthiot N, Goux A, Chambrin V, Deback C, Fior R, Raho Moussa M, Antoniotti O, Coban D, Cormerais L, Henquell C, Jacomet C, Lesens O, Chanoine N, Villmant A, Van Autreve JL, Bloch M, Ichou H, Manceron V, Mortier E, Zeng A, Bouvier-Alias M, Dominguez S, Lascaux-Cametez AS, Lelievre JD, Levy Y, Melica-Gregoire G, Pawlotsky JM, Pothier P, Waldner A, Inchiappa L, Verhaeghe A, Olivier B, Pathe JP, Berthe H, Mathez D, Favret V, Troisvallets D, Vandemeulebroucke E, Ceccaldi J, El Harif Z, Bocket L, Barbut P, Chaix F, Lambert C, Lambolez T, Miatezila J, Son O, Brunet P, Chappe C, Dhiver C, Lecomte V, Meddeb L, Poizot-Martin I, Tamalet C, Valadier J, Beck-Wirth G, Benomar M, Delarbre JM, Peter JM, Bevilacqua S, Venard V, Daneluzzi V, Idri N, Montoya B, Ferre V, Garnier E, Hue H, Larmet L, Point P, Raffi F, Reliqiet V, Rodallec A, Secher S, Amoyel P, Botton E, Janowski M, Le Cocguic Y, Deleplanque P, Descamps JM, Lapine M, Sunder S, Chansombat M, Charpentier C, Damond F, Diallo B, Duval X, Julia Z, Landman R, Legac S, Rioux C, Yeni P, Krivine A, Blanche P, Cros A, Gazalet P, Ghosn J, Krivine A, Sobel A, Bercot B, Diemer M, Parrinello M, Bey Boumezrag C, Bodard L, Gibert S, Huche FX, Raffenne L, Strebler M, Blanc C, Bourzam E, Hansel B, Lupin C, Wirden M, Bourzam E, Collias L, Effa J, Jung C, Pavie J, Pere H, Si Mohamed A, Delaugerre C, Gerard L, Loze B, Maylin S, Nabias R, Ponscarme D, Deleuze J, Rozenberg F, Bachour B, Bani-Sadr F, Chas J, Hamidi M, Kherallah L, Le Nagat S, Le Pendeven C, Moreau F, Nicolas JC, Schneider V, Tabone MD, Vaudre G, Giraudeau G, Le Moal G, Plainchamp D, Blondin G, Dorval I, Duthe JC, Perfezou P, Berger JL, Brodard V, Kmiec I, Rouger C, Strady C, Chappelin JM, Maillard A, Ratajczak M, Debab Y, De Oliveira F, Depatureaux A, Gueit I, Lemee V, Theron D, Pasdeloup I, Camps P, Bigaillon C, Ficko C, Imbert C, Rapp C, Grand C, Michau C, Bornarel D, Devillier P, Farfour E, Majerholc C, Vignon D, Zucman D, El Addouli M, Danjoux MF, Journe J, Leveneur Y, Marchou B, Nicot F, Prevoteau Du Clary F, Bonne S., Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Dupuis, Christine

Subjects
0301 basic medicine, Microbiology (medical), Cart, Adult, Male, medicine.medical_specialty, Anti-HIV Agents, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Internal medicine, Medicine, Humans, Protease inhibitor (pharmacology), Survival analysis, Reverse-transcriptase inhibitor, business.industry, Genetic Variation, Middle Aged, Viral Load, 030112 virology, Antiretroviral therapy, 3. Good health, CD4 Lymphocyte Count, Regimen, 030104 developmental biology, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, HIV-1, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business, Viral load, medicine.drug
Abstract

International audience; Background:To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients.Methods:Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL)

Published
2018
Full Text
View/download PDF

3. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

Author

Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, and Atlan C

Subjects
Adolescent, Adult, Female, Fibrinolysis, Humans, Male, Metformin pharmacology, Middle Aged, Glycoproteins blood, Insulin blood, Obesity blood, Plasminogen Activators antagonists & inhibitors, Plasminogen Inactivators, Triglycerides blood
Abstract

Low fibrinolytic activity, as measured by euglobulin (EFA), has been observed in obese subjects, and hypofibrinolysis may play a role in the pathogenesis of atherosclerosis and its complications. Blood fibrinolytic activity is regulated through a complex system of activators and inhibitors, especially plasminogen activator inhibitors (PA Inhibitors). In a group of 35 non-diabetic subjects with a wide range of body mass index (BMI), EFA was negatively correlated, and PA Inhibitor activity positively correlated, with BMI and plasma insulin levels. In a population of 49 non-diabetic obese women (differing from a control group of normal weight by lower EFA and higher level, of PA Inhibitor activity, plasma insulin and triglyceride), the PA Inhibitor activity was positively correlated with BMI, insulin and triglyceride. The increase in PA Inhibitor activity was associated with a high value of PA Inhibitor 1 antigen measured by an immuno-radiometric assay, indicating that the increased activity was due to a high level of circulating PA Inhibitor 1. Plasma insulin was lowered in obese non-diabetic subjects, without modification of the body weight, by a 24 hour fast or by treatment with Metformin. After 24 hours' fast, ten obese subjects had lower levels of insulin and PA Inhibitor activity and an increase in EFA. Treatment for 15 days by 1.75 g Metformin (or placebo), on a weight maintaining diet, induced, in the Metformin group, a decrease in plasma insulin, triglyceride and PA Inhibitor activity and an increase in EFA, while no change was observed in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1987

4. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.

Author

Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, and Collen D

Subjects
Adult, Aged, Female, Fibrinolysis, Humans, Male, Middle Aged, Plasminogen Inactivators, Serum Globulins analysis, Thrombophlebitis etiology, Tissue Plasminogen Activator antagonists & inhibitors, Triglycerides blood, Glycoproteins metabolism, Thrombophlebitis blood, Tissue Plasminogen Activator deficiency
Abstract

The fibrinolytic system was investigated in 120 patients with spontaneous or recurrent deep vein thrombosis (DVT) without any known organic disease able to explain by itself the occurrence of a thrombosis and without any known defect of antithrombin III, Heparin Cofactor II, Protein C, or Protein S. The assays included: Euglobulin fibrinolytic activity (EFA), tissue-type plasminogen activator related antigen (t-PA-Ag) and plasminogen activator inhibitor activity (PA inhibitor), which were measured before and after 10 min of venous occlusion (V.O.). On the basis of the results, the patients could be classified in 3 groups: good responders with an at least two-fold increase of EFA after venous occlusion (n = 76), poor responders with a lesser increase of EFA due to deficient release of t-PA (n = 12), and poor responders with a normal t-PA release but an increased level of PA-Inhibitor (n = 32). The poor responders due to deficient t-PA release (10% of total) had a higher incidence of recurrence of deep vein thrombosis, than the other groups (p less than 0.01). An overall correlation was found between the level of PA-Inhibitor activity and the triglyceride level (r = 0.40, p less than 0.01), suggesting that these elevations may be due to a common cause, at least in some of the patients. It is concluded that a poor fibrinolytic response to venous occlusion occurs in 35 percent of DVT patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1987

5. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.

Author

Vague P, Juhan-Vague I, Alessi MC, Badier C, and Valadier J

Subjects
Adolescent, Adult, Blood Glucose analysis, Clinical Trials as Topic, Female, Humans, Metformin therapeutic use, Middle Aged, Plasminogen Inactivators, Reference Values, Fibrinolysis drug effects, Glycoproteins blood, Insulin blood, Metformin pharmacology, Obesity blood, Triglycerides blood
Abstract

We have previously observed a positive correlation between Plasminogen Activator Inhibition capacity (PA Inhibition), Body Mass Index (BMI) and plasma insulin levels in a population of non diabetic subjects. The anti diabetic biguanide Metformin which decreases insulin resistance has been reported to increase the blood fibrinolytic activity. Therefore we have studied the effect of Metformin on PA Inhibition levels in obese subjects with normal glucose tolerance. Eighteen obese women (O) (BMI: 31.4 +/- 1.13, m +/- S.E.M.) were compared to age matched controls (C) (BMI: 20.2 +/- 0.8) and randomized to a 15 days treatment by Metformin (M) (1.7 g/day) or placebo (P) in a double blind study while on a weight maintaining diet. O compared to C had higher levels (m +/- S.E.M.) of PA Inhibition (9 +/- 1.8 IU/ml, versus 2.88 +/- 0.29 p less than 0.01), lower euglobulin fibrinolytic activity (EFA) (4.95 +/- 1.17 mm versus 9 +/- 0.29 p less than 0.05), higher plasma insulin (24.1 +/- 2.1. uU/ml), versus 12 +/- 1 p less than 0.01) and triglyceride (1.32 +/- 0.16 mmol/l, versus 0.8 +/- 0.08 p less than 0.05). After 15 days of treatment, in group M a significant decrease in PA Inhibition (5.51 +/- 1.4, versus 9.48 +/- 2.1 p less than 0.05) in plasma insulin (18.5 +/- 0.1, versus 24.5 +/- 3.5, p less than 0.05) and plasma triglyceride (1.08 +/- 0.1, versus 1.47 +/- 0.3 p less than 0.05) and an increase in EFA (6.50 +/- 0.28, versus 5.25 +/- 0.35 p less than 0.05) were observed. No significant variation was observed in group P.

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results